SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival

Leukemia. 2009 Oct;23(10):1929-32. doi: 10.1038/leu.2009.113. Epub 2009 May 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Cytarabine / therapeutic use*
  • Cytidine Deaminase / genetics*
  • Deoxycytidine Kinase / genetics*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / enzymology
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Middle Aged
  • Nucleoside Deaminases / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis
  • Survival Rate
  • Treatment Outcome
  • Young Adult

Substances

  • Antimetabolites, Antineoplastic
  • Cytarabine
  • Deoxycytidine Kinase
  • Nucleoside Deaminases
  • Cytidine Deaminase
  • deoxycytidine deaminase